Hepatitis B virus DNA in patients with hepatitis B-related liver cirrhosis with or without hepatocellular carcinomas: A matched case-control study

Journal of Digestive Diseases

Volumn 10, Issue 2, 2009, Pages 138-144

  Xu, Jing ^a   Lin, Yong ^a   Wang, Yi Ping ^a   Chen, Yue Xiang ^a   Shi, Bin ^a   Lu, Jian ^b   Xie, Wei Fen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HBV DNA; Hepatitis B virus; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIRUS LOAD;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 65449118748     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00376.x     Document Type: Article

References (30)

1. EASL International Consensus Conference on Hepatitis B. Consensus statement. J Hepatol 2003; 38: 533-40.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterol 2004; 127: S35-50.
4. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-52.
5. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82.
6. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B. a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58-61.
7. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
8. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
9. De Mitri MS, Bernardi M. Predicting the development of hepatocellular cancer in hepatitis B carriers. Gut 2008; 57: 12-15.
10. Chen CH, Hung CH, Lee CM et al. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterol 2007; 133: 1466-74.
11. Yu MW, Yeh SH, Chen PJ et.al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005; 97: 265-72.
12. Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92: 607-12.
13. Wu CH, Yu MW, Lin CL et al. Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men. Carcinogenesis 2008; 29: 106-12.
14. Ishikawa T, Ichida T, Yamagiwa S et al. High viral loads, serum alanine aminotransferase and gender are predictive factors for the development of hepatocellular carcinoma from viral compensated liver cirrhosis. J Gastroenterol Hepatol 2001; 16: 1274-81.
15. Ikeda K, Arase Y, Kobayashi M et al. Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. Intervirology 2003; 46: 96-104.
16. Matsumoto A, Tanaka E, Rokuhara A et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B. A multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
17. Liaw Y-F, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
18. Ikeda K, Saitoh S, Suzuki Y et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer 1998; 82: 827-35.
19. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 2006; 130: 678-86.
20. Chen G, Lin W, Shen F et al. Past HBV load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-803.
21. Fung J, Yuen MF, Yuen CH, Wong KH, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B. A case-control study. Aliment Pharmacol Ther 2007; 26: 377-82.
22. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-95.
23. Mahmood S, Niiyama G, Kamei A et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005; 25: 220-5.
24. Ohata K, Hamasaki K, Toriyama K et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-5.
25. Ikada K, Marusawa H, Osaki Y et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study. Ann Intern Med 2007; 146: 649-56.
26. Chan HLY, Chim AML, Lau JTF, Hui AY, Wong VWS, Sung JYS. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 2006; 101: 1516-23.
27. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B. A multicenter study. J Hepatol 1994; 21: 656-66.
28. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 1408-15.
29. Sigal SH, Ala A, Ivanov K et al. Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy. Liver Transpl 2005; 11: 82-8.
30. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-12.